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Prevention of Trypanosoma cruzi infection in mammals likely depends on either prevention of the invading 
trypomastigotes from infecting host cells or the rapid recognition and killing of the newly infected cells by T. cruzi-
specific T cells. We show here that multiple rounds of infection and cure (by drug therapy) fails to protect mice from 
reinfection, despite the generation of potent T cell responses. This disappointing result is similar to that obtained 
with many other vaccine protocols used in attempts to protect animals from T. cruzi infection. We have previously 
shown that immune recognition of T. cruzi infection is significantly delayed both at the systemic level and at the level 
of the infected host cell. The systemic delay appears to be the result of a stealth infection process that fails to trigger 
substantial innate recognition mechanisms while the delay at the cellular level is related to the immunodominance 
of highly variable gene family proteins, in particular those of the trans-sialidase family. Here we discuss how these 
previous studies and the new findings herein impact our thoughts on the potential of prophylactic vaccination to 
serve a productive role in the prevention of T. cruzi infection and Chagas disease.
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Vaccination to a wide range of bacterial and viral in-
fections has without question saved 100’s of millions of 
lives and many billions of dollars in treatment costs and 
lost productivity (Rappuoli et al. 2014). So it is expected 
that the ultimate goal for immunological studies into any 
animal pathogen has as its ultimate goal, the develop-
ment of a highly effective prophylactic vaccine. Unfor-
tunately such vaccines for human parasitic diseases have 
as yet alluded researchers. This is not for lack of effort in 
most cases. With respect to T. cruzi, the agent of human 
Chagas disease, there have been considerable efforts ap-
plying a broad range of technologies [reviewed in (Qui-
jano-Hernandez & Dumonteil 2011, Vazquez-Chagoyan 
et al. 2011)]. Many vaccines have been shown to increase 
the rate and quality of the infection control in animal 
models, but none have actually prevented the establish-
ment of the infection. In effect, these vaccines do no bet-
ter than what the natural immune system ultimately does 
on its own - establish very good pathogen control, but 
rarely elimination of the infection. And because it is per-
sistent infection rather than acute lethality that is by far 
the primary cause of morbidity and mortality in Chagas 
disease, these partially effective vaccines would seem 
to have rather limited utility, particularly for preventing 
human disease. Herein we consider reasons why this is 
the case with T. cruzi infection and Chagas disease and 
consider whether there might be diseases for which vac-
cines will remain elusive, irrespective of the knowledge 
and technologies brought to bear.
A number of conditions have to be met and informa-
tion known in order to assess the potential for an effec-
tive prophylactic/sterilising vaccine. Among these are 
(i) Are the mechanisms of immune control understood? 
(ii) Does the normal response to infection at least occa-
sionally result in parasitological cure? and (iii) Are those 
who resolve/cure the infection resistant to reinfection?
Addressing these questions, there is a reasonably clear 
understanding of the immune effector mechanism that 
are particularly important in immune control of T. cruzi 
(Tarleton 2007). Whether these responses can achieve 
parasitological cure, the answer for T. cruzi appears to be 
yes - both in humans and in animal models “spontane-
ous cure” of infection (e.g. complete parasite clearance 
without chemical or immunological interventions) does 
occur (Francolino et al. 2003, Dias et al. 2008, Bertocchi 
et al. 2013, Tarleton 2013). However such cures take a 
considerable period of time and are also relatively rare. 
Thus, although the standard infection with T. cruzi is 
life-long, with low parasite burden, occasionally the bal-
ance tips toward complete parasite elimination. It is not 
clear why some infections are cured while most are not 
and the immunological correlates of these cures are not 
known. It may simply be that this is a war of attrition, 
with the host occasionally prevailing outright. For a vac-
cine to be effective in T. cruzi infection it has to force 
the immune system to routinely and dependably wage a 
more effective battle without generating greater damage. 
Without better knowledge of the immunological corre-
lates of cure, this may be difficult to achieve.
Because spontaneous cures are rare, determining 
whether hosts that completely resolve the infection are 
resistant to reinfection has not been previously investi-
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MATERIALS AND METHODS
Mice, parasites and infections - C57BL/6 (Ly5.2+) 
(B6) mice were purchased from National Cancer Insti-
tute at Frederick (USA) and were maintained in the Uni-
versity of Georgia animal facility in microisolator cages 
under specific pathogen-free conditions. Tissue culture 
trypomastigotes (TCT) of the CL strain of T. cruzi were 
obtained from passage through Vero cells. Mice were 
infected intraperitoneally (i.p.) with 1,000 Brazil strain 
TCT and sacrificed by CO2 inhalation at different time 
points post-infection. Mice were reinfected i.p with 103 
TCT of T. cruzi CL strain at different time points post-
infection. In some experiments mice were challenged 
in the hind foot pads with 2.5 × 105 T. cruzi tdTomato 
trypomastigotes as described previously and the fluores-
cent intensity as a surrogate of parasite load was meas-
ured using a whole animal imaging system (Maestro2 In 
Vivo Imaging System CRi, USA) (Canavaci et al. 2010).
BZ treatment - N-Benzyl-2-nitroimidazole acetamide 
(benznidazole; Rochagan, Roche, Brazil) was used as a 
trypanocidal drug. Mice were treated orally with daily 
doses of BZ of 100 mg/kg of body weight for 40 days 
[15-55 days post-infection (dpi)]. BZ was prepared by pul-
verisation of one tablet containing 100 mg of the active 
principle, followed by suspension in distilled water. Each 
mouse received 0.20 mL of this suspension by gavage.
Assessment of treatment efficacy - Mice were immu-
nosuppressed with cyclophosphamide (200 mg/kg/day) 
i.p. at two-three day intervals for a total of four doses. 
Following immunosuppression, blood was collected 
via tail vein and the number of parasites was quanti-
fied using a Neubauer haemocytometer. Survival was 
monitored daily. The DNA preparation, generation of 
polymerase chain reaction (PCR) standards and detec-
tion of parasite tissue load by real-time PCR was carried 
out as described previously (Cummings et al. 2003, Bus-
tamante et al. 2008). Skeletal, heart and fat tissues were 
collected at various time points post-treatment and fixed 
in 10% buffered formalin. Sections (5 μm) from paraf-
fin-embedded tissues were stained with haematoxylin 
and eosin for histopathological analysis.
T cell phenotyping - Red blood cells (RBCs) in sin-
gle cell suspensions of spleen cells (SC) were lysed in a 
hypotonic ammonium chloride solution and washed in 
staining buffer {2% bovine serum albumin, 0.02% azide 
in phosphate buffered saline (PBS) [PAB]}.
In some cases, mouse peripheral blood was obtained 
by retro-orbital venipuncture, collected in Na citrate so-
lution and washed in PAB. Whole blood was incubated 
with tetramer-PE and the following labelled Abs: anti-
CD44 FITC, anti-KLRG1 PECy7, anti-CD8 EFluor 450, 
anti-CD127 APC (eBioscience, USA). Cells were also 
stained with anti-CD4, anti-CD11b and anti-B220 (Calt-
ag-Invitrogen Laboratories, USA) for use as an exclusion 
channel. Cells were stained for 45 min at 4ºC in the dark, 
washed twice in PAB and fixed in 2% formaldehyde. 
RBCs were lysed in a hypotonic ammonium chloride 
solution after washing twice in PAB. At least 500,000 
cells were acquired using a Cyan flow cytometer (Da-
koCytomation, USA) and analysed with FlowJo soft-
ware (Tree Star Inc, USA). MHC I tetramers TSKB20 
(ANYKFTLV/Kb) was synthesised at the Tetramer Core 
Facility (Emory University, USA).
Intracellular cytokine staining - SC from naïve, un-
treated/chronic or treated/cured mice were stimulated with 
T. cruzi peptides (5 μM) at 37ºC for 5 h in the presence of 
Brefeldin A (GolgiPlug; BD Pharmingen, USA). T. cruzi 
peptides used in this study were TSKB20 (ANYKFTLV) 
and TSKB74 (VNYDFTLV) (Martin et al. 2006). Cells 
were surface stained with anti-CD8 EFluor 450 (eBiosci-
ence) and intracellular cytokine staining was performed 
with anti-interferon-γ APC and with a Cytofix/Ctyoperm 
kit (BD Biosciences, USA) in accordance with the man-
ufacturer’s instructions. At least 250,000 lymphocyte 
events were acquired and analysed as above.
In vivo cytotoxicity assay - SC from naïve mice 
were incubated either with the T. cruzi peptide TSKB20 
(ANYKFTLV), TSKB74 (VNYDFTLV) or with no 
peptide for 1 h at 37ºC. Cells were washed twice with 
PBS and incubated with 2.5 μM CFSE (CFSEhigh) for 
TSKB20 peptide-loaded cells, 1.0 μM CFSE (CFSEint), 
for TSKB74 peptide-loaded cells or 0.25 μM CFSE (CF-
SElow) for unpulsed cells for 3 min at room temperature. 
The CFSE was quenched with FBS and the CFSElow and 
CFSEhigh cells were combined and transferred intrave-
nously into naïve, untreated/chronic and treated/cured 
mice. SCs were harvested after 16 h and CFSEhigh, CF-
SEint and CFSElow cells were detected by flow cytometry. 
The percentage of specific killing was determined us-
ing the formula: {1- [(%CFSElow naïve/%CFSEhigh naïve)/
(%CFSElow chronic/%CFSEhigh chronic)]} 100%.
Ethics - All animal protocols were approved by the 
University of Georgia Institutional Animal Care and 
Use Committee.
RESULTS AND DISCUSSION
Effective vaccines faithfully mimic the immune pro-
tection afforded by survival of a full-fledged infection. 
Since complete spontaneous clearance of T. cruzi infec-
tion is rare, we simulated the immunity induced by reso-
lution of infection by curing established infections using 
BZ treatment. Our previous studies have established the 
conditions for achieving and methods to monitor parasito-
logical cure using this approach (Bustamante et al. 2008). 
In initial experiments, mice were infected with 103 try-
pomastigotes and BZ treatment was initiated on day 15 
post-treatment and then challenge infection was delivered 
~150 days after the completion of drug treatment (Fig. 
1A). Mice were then immunosuppressed ~45 days after 
challenge to reveal persistence of infection as assessed 
by parasites in blood and tissues. Previous studies have 
established this immunosuppression protocol as a stan-
dard for detecting persistent infection and for determin-
ing the curative potential of candidate drugs (Bustamante 
et al. 2008, 2014). As shown in Fig. 1B, treated but not 
re-challenged mice were free of infection, demonstrating 
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again the ability of this BZ treatment regimen to achieve 
parasitological cure. However both persistently infected 
(untreated) and infected/cured mice (treated) exhibited 
parasites in the blood and in tissues following re-chal-
lenge (Fig. 1C). Thus, mice cured of T. cruzi infection are 
not resistant to reinfection with a low dose of T. cruzi.
To follow the reinfection process at the infection 
site more closely, we assessed initial protection using 
fluorescent protein-expressing parasites delivered into 
the footpads of single or multiple dose “immunised” as 
previously described (Collins et al. 2011) (Fig. 2A). As 
predicted, a single round of infection and cure provided 
essentially no protection based on the footpad infection 
model (Fig. 2B). In contrast, similar challenge infection 
in continuously infected mice (not BZ-treated group) 
resulted in more rapid control of the footpad challenge 
relative to either noninfected or infected/cured mice.
We then asked if boosting of the immune protection 
could be achieved by multiple rounds of infection and 
cure. Attainment of parasitological cure after each round 
of infection and treatment was confirmed by detection 
of predominantly CD127-expressing, T central memory 
phenotype T. cruzi-specific T cells in the blood of mice 
(Fig. 3A). Continuously infected mice maintained a rela-
tively stable and low level of CD127-expressing T cells 
specific for the immunodominant TSKb20 T. cruzi trans-
sialidase (ts)-derived epitope whereas drug-cured mice 
exhibited a decrease in the overall number of TSKb20-
specific T cells and an increasing proportion of CD127 
expression, indicative of the absence of continuous anti-
gen stimulation in these cured mice (Bustamante et al. 
2008) (Fig. 3A, B). Multiple rounds of infection and cure 
increased the ability of mice to control initial parasite 
growth in the footpad, with three rounds of infection and 
cure providing a level of protection nearly equivalent to 
that afforded by continuous infection (Fig. 2B, C).
Even nonvaccinated mice ultimately control T. cruzi 
at the initial infection site in the footpad resulting in the 
absence of detectable parasites by immunofluorescence 
at > 2 weeks post-infection (Fig. 2). To determine if the 
multiply infection/cured mice additionally were able to 
clear infection throughout the body (not just at the site of 
initial infection), mice were immunosuppressed and then 
reassessed for parasites in the blood and tissues using 
microscopy (Fig. 2E-G). As expected both the continu-
ously infected/challenged and the naïve/challenged mice 
had detectable parasitaemias following immunosuppres-
sion. However even mice submitted to three rounds of 
infection and cure failed to prevent the establishment of 
the infection following footpad challenge. The failure to 
prevent reinfection following one or two rounds of in-
fection/cure is also evident from the fact that mice chal-
lenged with a low dose (103) of T. cruzi i.p. show very low 
levels of CD127 expression on T. cruzi-specific T cells, 
indicative of a persistent antigen presence (Fig. 3A).
Fig. 1: Trypanosoma cruzi-infected and cured mice are not sterilely immune to reinfection. A: schematic representation of infection, treatment, re-
infection and immunosuppression. Mice infected for 15 days with 103 trypomastigotes of the T. cruzi CL strain were left untreated or were treated 
with a 40 day course of benznidazole (BZ) at 100 mg/kg/day. Mice were there challenge infected with the same strain/dose of T. cruzi or not chal-
lenged and then 45 days later (day 265 of the experiment) immunosuppressed with cyclophosphamide as previously described (Bustamante et al. 
2008); B: detection of parasites in blood or muscle tissue (C) two weeks after immunosuppression indicates the failure of infection/cure protocol 
to protect mice from challenge infection. Treated but not-re-challenged mice had no detectable parasitaemia following immunosuppression (B) 
indicating the ability of the BZ treatment to provide parasitological cure; C: histological sections of the skeletal muscle at 280 days post-infection 
(dpi). Presence of absence of tissue parasites was confirmed by quantitative polymerase chain reaction (data not shown). Bar = 200 μm.
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Although immunity induced by cure of an initial in-
fection is generally the standard against which vaccines 
are measured, there are multiple reasons why the infec-
tion/cure protocol used herein failed to provide sterilising 
immunity. To exclude the possibility that immune effec-
tors might not be generated, or are lost after BZ-induced 
cure, we monitored effector functions in T. cruzi-specific 
T cells during the infection cure cycle. The boost in the 
frequency of T. cruzi-specific T cells in cured mice fol-
lowing each round of reinfection is indicative of sus-
tained and competent T cell memory following infection 
cure (Fig. 3B). Although the overall frequency of T. cru-
zi-specific CD8+ T cells decreases, as expected following 
infection cure (Bustamante et al. 2008) (Figs 3B, 4A), the 
quality of these memory T cells is evidenced by their in 
vivo cytolytic activity (Fig. 4B) and ex vivo cytokine pro-
duction in response to T. cruzi epitopes (Fig. 4C). Thus 
the failure of the infection cure protocol to provide pro-
tection is not due to the absence of an inducible effector T 
cell population that could be recalled upon challenge.
The argument could be made that the immunity in-
duced by the infection/cure protocol used here induces 
an insufficient and/or poorly targeted immune response. 
The enhanced protection conveyed by active infection 
Fig. 2: enhanced infection control acquired after three cured infections. A: schematic representation of infection, treatment and reinfection. Red 
arrows indicate points at which a subset of mice was immunosuppressed to assess infection status (B, D, F). Parasite load at the site of the infec-
tion assessed by quantification of the fluorescent signal from mice primarily infected with 1 × 103 CL wild-type parasites that underwent one, 
two or three cured infections and their untreated counterparts submitted to challenged in the hind foot pads with 2.5 × 105 Trypanosoma cruzi 
tdTomato trypomastigotes (C, E, G). Parasitaemias in mice described in B, D and F at ~15 days after administration of the immunosuppressant 
cyclophosphamide; BZ: benznidazole; dpi: days post-infection.
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relative to cured infection evident in the footpad chal-
lenge model might suggest that higher number of para-
site-specific T cells, effector T cells, rather than memory 
T cells or effector mechanisms not measured in these 
assays, may be required for optimal infection control. 
However it is apparent in other studies (Bustamante et 
al. 2002, 2007) that superinfection (a “new” infection in 
an already infected host) is not uncommon in the case 
of T. cruzi, indicating that simply having more effector 
T cells (as is the case during an active infection) rather 
than memory T cells (in cured infection) is not sufficient 
to prevent establishment of “new” infections. Thus, im-
munity induced by prior infection, whether cured or not, 
is insufficient to prevent reinfection.
We believe that the results of several recent studies 
shed some light on the failure of active infection and the 
infection/cure protocol used here, as well as other vac-
cine protocols in T. cruzi and may be informative with 
respect to defining the overall likelihood of developing 
competent prophylactic vaccines for T. cruzi infection. 
For the immune system to prevent the establishment of 
T. cruzi infection, the potentially protective response 
must either absolutely prevent parasites from infecting 
host cells, thus halting the replication of T. cruzi before 
it can begin or must rapidly identify and kill infected 
cells before the initial round of parasite replication can 
be completed (and the resulting expanded population of 
parasites spreads throughout the body).
With respect to the preventing host cell entry, the 
passive transfer of high-titre antibodies can reduce par-
asite loads (Franchin et al. 1997), presumably through 
the ability to target extracellular trypomastigotes for de-
struction by complement or phagocytic cells, or to block 
the ability of these parasites to invade host cells. How-
ever this approach has not been demonstrated to actually 
prevent infection and the antibodies produced during the 
course of acute and chronic infections, although contrib-
uting to immune control of the infection (Kumar & Tar-
leton 1998) clearly lack the ability to prevent the constant 
reinfection of host cells that maintains the infection. So 
the ability to generate a targeted antibody response suf-
ficient to block 100% of invading parasites seems ques-
tionable - certainly no previously tested method has.
Investigation of the early events in the generation of 
parasite-specific T cell responses in T. cruzi have provid-
ed some insights into how the naïve as well as the primed 
immune system deals with T. cruzi. Despite the strength 
and the focus of the CD8+ cells generated in T. cruzi in-
fection, this response is nevertheless extremely slow in 
developing (Padilla et al. 2009). This delay is evident in 
the initiation of proliferation and development of effec-
tor function in parasite-specific T cells, as well as in the 
recruitment of leukocytes into the draining lymph nodes. 
These observations suggest initially T. cruzi is infection 
occurs “under the radar”, failing to trigger significant 
recognition by pathogen sensors on with innate and adap-
tive immune responses depend. We have attributed this 
clandestine infection process by T. cruzi to two factors: 
(i) the mechanism of cell invasion by T. cruzi that oc-
curs without significant host cell damage and thus with 
little release of damage associated molecular patterns 
(DAMPs) and (ii) the absence of significant pathogen-
associated molecular patterns (PAMPs) in the invading T. 
cruzi trypomastigotes. These conclusions are supported 
the observation of the delayed generation of responses, 
the timing of which follows closely the destruction of 
host cells (with the consequent release of DAMPs) during 
the exit of parasites at four-five dpi. Additionally, initia-
tion of anti-T. cruzi T cell responses can be accelerated 
and enhanced by supplying bona fide PAMPs with the in-
fection, either by administration of ligands for TLR2 and 
TLR9 coincident with infection (Padilla et al. 2009) or by 
endogenous expression of classical bacterial PAMPs by 
T. cruzi (Kurup & Tarleton 2013).
The insufficiency of T. cruzi in triggering of innate 
immune sensors not only delays the initiation of respons-
es in newly infected hosts, but also has a long-lasting 
impact on the ultimate course of T. cruzi infection. In-
fections with T. cruzi lines expressing Salmonella flagel-
lin, a well-studied bacterial PAMP, control the infection 
better, exhibit much-reduced pathogen load and evidence 
of cure in some cases (Kurup & Tarleton 2013). The im-
plications of these results for the potential of vaccines to 
prevent T. cruzi infection are substantial. First, if T. cruzi 
can avoid eliciting an inflammatory response - at least 
Fig. 3: parasite-specific memory T cell responses in mice undergoing 
multiple rounds of infection and cure. A: expression of the memory 
maintenance marker CD127 in blood on CD8+ TSKB20-tetramer+ T 
cells from infected mice that underwent three cured infections and 
their untreated counterparts; B: the MHC-peptide tetramer of the im-
munodominant TSKB20/Kb epitope was used to detect Trypanosoma 
cruzi-specific CD8+ T cells in the blood of mice described above; BZ: 
benznidazole; dpi: days post-infection.
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Fig. 4: functional effector T cell responses in Trypanosoma cruzi-in-
fected and cured mice in the late stages of the infection. A: frequency 
of TSKB20/Kb+ T cells in the spleens of untreated or treated mice 615 
days post-infection (dpi) (560 days post-treatment); B: in vivo cytotox-
ic T lymphocyte activity on TSKB20 and TSKB74-pulsed targets 16 h 
after transfer to naïve, untreated or treated T. cruzi-infected mice (615 
dpi). Data are from representative individual mice. Numbers above 
the peaks are percentage of specific lysis calculated as described in 
the Material and Methods; C: intracellular cytokine staining for inter-
feron (IFN)-γ production by CD8+ T cells with or without stimulation 
with TSKB20 peptide in representative mice at 400 dpi. Numbers rep-
resent the percentage of CD8+ T cells producing IFN-γ.
until after completes the first round of replication in and 
release from host cells - then no level of pre-existing T 
cell immunity (i.e., vaccine-induced immunity) will be 
able to prevent establishment of the infection in a newly 
infected host or quickly extinguish that infection once it 
is established. Second, each time T. cruzi invades cells 
in a “new” site in an infected host (e.g. a site lacking 
primed effector cells) parasite proliferation would also be 
expected to proceed there unfettered until the inflamma-
tory signals generated by the destruction of the host cell 
recruit these effector cells beginning four-five days later 
(upon completion of the replication cycle). Indeed this 
trend is apparent in the footpad infection assays shown in 
Fig. 2; for the one and two-time infected/cured mice, as 
well as early infection in the continuously infected mice, 
there is essentially no control of parasite load detected in 
the infection site until after day 4 of infection.
A second potential complicating factor in immunity 
to T. cruzi and vaccine development is the targets of 
these immune responses. The major focus of both cel-
lular and humoral immune responses in T. cruzi infec-
tion are proteins encoded by large gene families. With 
respect to CD8+ T cell responses, epitopes encoded by 
the ts family of genes are strongly immunodominant 
(Martin et al. 2006). The high variability (the ts family 
is composed of  > 3,000 individual genes/gene fragments 
in the T. cruzi CL Brener genome) and the strain-specific 
variation and recombinational potential of these genes 
(P Weatherly et al., unpublished observations) makes the 
ts proteins moving targets for immune responses and 
thus a relatively poor choice as vaccine targets. Further-
more, we have recently reported that ts epitopes are not 
effectively presented by infected host cells until 24-48 h 
after host cell infection. In contrast, other nonvariant but 
sub-dominant immune targets from flagellar proteins 
are detected by T cells within 6 h after host cell inva-
sion (Kurup & Tarleton 2014). Thus the normal T cell 
response to T. cruzi is fixated on a set of molecules that 
are highly variable and that are not expressed until late 
in the cycle of host cell infection - a poor “choice” for the 
effective elimination of infected host cells.
Collectively, the data presented in these studies and 
previously reported suggest the following scenario of 
events in T. cruzi infection. Infection of naïve, previously 
infected or persistently infected hosts, or in new sites 
within an infected host, occurs with minimal triggering 
of innate immune sensors, thus allowing the establish-
ment of T. cruzi in these hosts/sites. T cell responses are 
generated and local inflammation is induced only after 
completion of a round of parasite replication and host cell 
destruction, which releases DAMPs and possibly PAM-
Ps. The anti-T. cruzi T cells that are normally induced in 
the infection target primarily highly variant proteins that 
are not effectively presented on host cells until late in the 
host cell infection process. Thus T cells that are induced 
by infection or vaccination are both not initially recruited 
to sites of infection and when they ultimately get to these 
sites, they do not have the specificities that allow them to 
rapidly identify infected host cells early in the infection 
process. Vaccination could be used to redirect T cell re-
sponses to nonvariant antigens, such as those encoded in 
flagellar proteins - this process has been shown to have 
some merit (Kurup & Tarleton 2014). However it is dif-
ficult to see how a vaccination can overcome the issue 
of the relatively silent invasion process used by T. cruzi. 
The best one might be able to hope for in an anti-T. cruzi 
vaccine is to enhance the rate of parasite clearance and 
reduce the time required to and frequency of cure of the 
infection - but not prevent the infection. While this would 
be an improvement, whether that is sufficient to justify a 
vaccine development program is uncertain.
The studies discussed here present the possibility that 
development of an effective prophylactic vaccine for T. 
cruzi may not be feasible. The incredible impact of vac-
cines in curbing deaths due to infectious agents notwith-
standing, it may just be that there are infections that will 
allude protection by prophylactic vaccination and Cha-
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the same problems as described here for prophylactic 
vaccines, as well as the concern of their utility given the 
availability of therapeutic drugs that can be highly ef-
fective, despite their variability and toxicities. Because 
T. cruzi infection is zoonotic and the fact that compan-
ion animals contribute significantly to its transmission 
to humans, transmission blocking vaccines that reduce 
pathogen load (without having to necessary eliminate 
the infection) have some promise. Lastly, related to the 
effectiveness of drugs to cure T. cruzi infection - as done 
in this study - it is important to note that hosts cured of 
T. cruzi infection are susceptible to reinfection. So the 
use and development of better methods of transmission 
control will continue to be a necessity if the impact of T. 
cruzi infection in humans is to be reduced.
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